Search Database ICD-O-3 Code Lists

Name

Histiocytic sarcoma

ICD-O-2 Morphology

9723/3: True histiocytic sarcoma
Effective 1992 - 2000

ICD-O-3 Morphology

9755/3: Histiocytic sarcoma
Effective 2001 and later

Reportable

for cases diagnosed 1992 and later

Primary Site(s)

See Module 7
Most common sites of involvement: lymph nodes, skin, intestinal tract, soft tissue

Coding Manual: Hematopoietic Coding Manual (PDF)

Abstractor Notes

Rarely, systemic presentation with multiple sites of involvement may be seen, and is sometimes referred to as "malignant histiocytosis".

This is a very aggressive neoplasm with a usually poor response to therapy.

Diagnostic Confirmation

This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.

Grade

Not Applicable

Module Rule

None

Alternate Names

Histiocytic medullary reticulosis [OBS]
Malignant histiocytosis
Monocytic sarcoma
True histiocytic lymphoma
True histiocytic sarcoma

Definition

Histiocytic sarcoma is a malignant proliferation of cells showing morphological and immunophenotypic features of mature tissue histiocytes. Neoplastic proliferations associated with acute monocytic leukemia are excluded.

Definitive Diagnostic Methods

Genetic testing
Histologic confirmation
Immunophenotyping

Genetics Data

Clonal Ig rearrangements
TCR rearrangements are lacking

Immunophenotyping

Absence of markers from non-histiocytic cells
CD4+ (expression/positive)
CD15+ (expression/positive)
CD45+ (expression/positive)
CD45RO+ (expression/positive)
CD68 (KP1 and PGM1)+ (expression/positive)
CD163+ (expression/positive)
HLA-DR+ (expression/positive)
Lysozyme+ (expression/positive)

Treatments

Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Hormone therapy
Radiation therapy
Surgery

Transformations to

There are no known transformations

Transformations from

There are no known transformations

Same Primaries

Corresponding ICD-9 Codes

202.3 Malignant histiocytosis

Corresponding ICD-10 Codes

C96.3 True histiocytic lymphoma

Corresponding ICD-10-CM Codes (U.S. only)

C96.A Histiocytic sarcoma (effective October 01, 2015)

Signs and Symptoms

Fever
Hepatosplenomegaly
Lymphadenopathy
Lytic lesions on bones
Pancytopenia
Skin lesions (solitary and innumerable)
Weight loss

Diagnostic Exams

Biopsy
Blood chemistry studies
Bone marrow aspiration and biopsy
Bone scan
BRAF testing
CT (CAT) scan
Endoscopy
Flow cytometry
Immunophenotyping
Liver function test
Neurological exam
PET (positron emission tomography) scan
Ultrasound exam
Urinalysis
Water deprivation test

Progression and Transformation

Most patients die of progressive involvement reflecting the high clinical stage at presentation (stage III-IV) in the majority of patients

Epidemiology and Mortality

Age: 52 years median age (infancy to elderly age range)
Incidence: rare, limited number of reported cases
Sex: male predominance
Survival: generally poor, 60-80% of patients die from progressive involvement

Sources

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Histiocytic and dendritic cell neoplasms
Pages: 468-470

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577

National Cancer Institute
Section: General Information About Adult Non-Hodgkin Lymphoma (NHL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq
Glossary